Selective Imaging of Matrix Metalloproteinase-13 to Detect Extracellular Matrix Remodeling in Atherosclerotic Lesions | springermedizin.de

Springer Medizin

nach oben

Molecular Imaging and Biology

Erschienen in:

06.07.2021 | Research Article

Selective Imaging of Matrix Metalloproteinase-13 to Detect Extracellular Matrix Remodeling in Atherosclerotic Lesions

verfasst von: Ariel Buchler, Maxime Munch, Gedaliah Farber, Xiaoling Zhao, Rami Al-Haddad, Eadan Farber, Benjamin H. Rotstein

Erschienen in: Molecular Imaging and Biology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Overexpression and activation of matrix metalloproteinase-13 (MMP-13) within atheroma increases susceptibility to plaque rupture, a major cause of severe cardiovascular complications. In comparison to pan-MMP targeting [¹⁸F]BR-351, we evaluated the potential for [¹⁸F]FMBP, a selective PET radiotracer for MMP-13, to detect extracellular matrix (ECM) remodeling in vascular plaques possessing markers of inflammation.

Procedures

[¹⁸F]FMBP and [¹⁸F]BR-351 were initially assessed in vitro by incubation with en face aortae from 8 month-old atherogenic ApoE^−/− mice. Ex vivo biodistributions, plasma metabolite analyses, and ex vivo autoradiography were analogously performed 30 min after intravenous radiotracer administration in age-matched C57Bl/6 and ApoE^−/− mice under baseline or homologous blocking conditions. En face aortae were subsequently stained with Oil Red O (ORO), sectioned, and subject to immunofluorescence staining for Mac-2 and MMP-13.

Results

High-resolution autoradiographic image analysis demonstrated target specificity and regional concordance to lipid-rich lesions. Biodistribution studies revealed hepatobiliary excretion, low accumulation of radioactivity in non-excretory organs, and few differences between strains and conditions in non-target organs. Plasma metabolite analyses uncovered that [¹⁸F]FMBP exhibited excellent in vivo stability (≥74% intact) while [¹⁸F]BR-351 was extensively metabolized (≤37% intact). Ex vivo autoradiography and histology of en face aortae revealed that [¹⁸F]FMBP, relative to [¹⁸F]BR-351, exhibited 2.9-fold greater lesion uptake, substantial specific binding (68%), and improved sensitivity to atherosclerotic tissue (2.9-fold vs 2.1-fold). Immunofluorescent staining of aortic en face cross sections demonstrated elevated Mac-2 and MMP-13-positive areas within atherosclerotic lesions identified by [¹⁸F]FMBP ex vivo autoradiography.

Conclusions

While both radiotracers successfully identified atherosclerotic plaques, [¹⁸F]FMBP showed superior specificity and sensitivity for lesions possessing features of destructive plaque remodeling. The detection of ECM remodeling by selective targeting of MMP-13 may enable characterization of high-risk atherosclerosis featuring elevated collagenase activity.

Anzeige

Nur mit Berechtigung zugänglich

1.

Bonnans C, Chou J, Werb Z (2014) Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 15:786–801PubMedPubMedCentralCrossRef

2.

Löffek S, Schilling O, Franzke C-W (2011) Biological role of matrix metalloproteinases: a critical balance. Eur Respir J 38:191–208PubMedCrossRef

3.

Li H, Wang D, Yuan Y, Min J (2017) New insights on the MMP-13 regulatory network in the pathogenesis of early osteoarthritis. Arthritis Res Ther 19:248PubMedPubMedCentralCrossRef

4.

Hu J, Van den Steen PE, Sang Q-XA, Opdenakker G (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6:480–498PubMedCrossRef

5.

Johnson JL (2017) Metalloproteinases in Atherosclerosis. Eur J Pharmacol 816:93–106PubMedCrossRef

6.

Giannakou S, Angelidis G, Tsougos I, Valotassiou V, Kappas K, Georgoulias P (2020) Pet tracers for vulnerable plaque imaging. Ann Nucl Med 34:305–313PubMedCrossRef

7.

Heo R, Nakazato R, Kalra D, Min JK (2014) Noninvasive imaging in coronary artery disease. Semin Nucl Med 44:398–409PubMedPubMedCentralCrossRef

8.

Owen DRJ, Lindsay AC, Choudhury RP, Fayad ZA (2011) Imaging of atherosclerosis. Annu Rev Med 62:25–40PubMedPubMedCentralCrossRef

9.

Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874PubMedCrossRef

10.

Sukhova GK, Schönbeck U, Rabkin E et al (1999) Evidence for Increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 99:2503–2509PubMedCrossRef

11.

Lessner SM, Galis ZS (2004) Matrix metalloproteinases and vascular endothelium-mononuclear cell close encounters. Trends Cardiovasc Med 14:105–111PubMedCrossRef

12.

Newby AC (2012) Matrix metalloproteinase inhibition therapy for vascular diseases. Vasc Pharmacol 56:232–244CrossRef

13.

Schaar J (2004) Terminology for high-risk and vulnerable coronary artery plaques. Eur Heart J 25:1077–1082PubMedCrossRef

14.

Newby AC (2014) Proteinases and plaque rupture: unblocking the road to translation. Curr Opin Lipidol 25:358–366PubMedCrossRef

15.

Quillard T, Araújo HA, Franck G, Tesmenitsky Y, Libby P (2014) Matrix metalloproteinase-13 predominates over matrix metalloproteinase-8 as the functional interstitial collagenase in mouse atheromata. Arterioscler Thromb Vasc Biol 34:1179–1186PubMedPubMedCentralCrossRef

16.

Quillard T, Tesmenitsky Y, Croce K, Travers R, Shvartz E, Koskinas KC, Sukhova GK, Aikawa E, Aikawa M, Libby P (2011) Selective inhibition of matrix metalloproteinase-13 Increases collagen content of established mouse Atherosclerosis. Arterioscler Thromb Vasc Biol 31:2464–2472PubMedPubMedCentralCrossRef

17.

Deguchi J, Aikawa E, Libby P et al (2005) Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation 112:2708–2715PubMedCrossRef

18.

Vazquez N, Missault S, Vangestel C, Deleye S, Thomae D, van der Veken P, Augustyns K, Staelens S, Dedeurwaerdere S, wyffels L (2017) Evaluation of [18F]BR420 and [18F]BR351 as radiotracers for MMP-9 imaging in colorectal cancer. J Label Compd Radiopharm 60:69–79CrossRef

19.

Ye Y, Toczek J, Gona K, Kim HY, Han J, Razavian M, Golestani R, Zhang J, Wu TL, Ghosh M, Jung JJ, Sadeghi MM (2018) Novel arginine-containing macrocyclic MMP inhibitors: synthesis, ^99mTc-labeling, and evaluation. Sci Rep 8:11647PubMedPubMedCentralCrossRef

20.

auf dem Keller U, Bellac CL, Li Y et al (2010) Novel matrix metalloproteinase inhibitor [18F]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer. Cancer Res 70:7562–7569CrossRef

21.

Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ (2000) A Matrix Metalloproteinase Induction/Activation System Exists in the Human Left Ventricular Myocardium and Is Upregulated in Heart Failure. Circulation 102:1944–1949PubMedCrossRef

22.

Hugenberg V, Wagner S, Kopka K, Schäfers M, Schuit RC, Windhorst AD, Hermann S (2017) Radiolabeled Selective matrix metalloproteinase 13 (MMP-13) inhibitors: (radio)syntheses and in vitro and first in vivo evaluation. J Med Chem 60:307–321PubMedCrossRef

23.

Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M (2014) Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach. J Med Chem 57:8886–8902PubMedCrossRef

24.

Rangasamy L, Di Geronimo B, Ortín I et al (2019) Molecular Imaging probes based on matrix metalloproteinase inhibitors (MMPIs). Molecules 24:2982PubMedCentralCrossRef

25.

Engel CK, Pirard B, Schimanski S, Kirsch R, Habermann J, Klingler O, Schlotte V, Weithmann KU, Wendt KU (2005) Structural basis for the highly selective inhibition of MMP-13. Chem Biol 12:181–189PubMedCrossRef

26.

Wagner S, Breyholz H-J, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K (2007) Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N -hydroxy-2( R )-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET. J Med Chem 50:5752–5764PubMedCrossRef

27.

Zinnhardt B, Pigeon H, Thézé B, Viel T, Wachsmuth L, Fricke IB, Schelhaas S, Honold L, Schwegmann K, Wagner S, Faust A, Faber C, Kuhlmann MT, Hermann S, Schäfers M, Winkeler A, Jacobs AH (2017) Combined PET imaging of the inflammatory tumor microenvironment identifies margins of unique radiotracer uptake. Cancer Res 77:1831–1841PubMedCrossRef

28.

Zinnhardt B, Viel T, Wachsmuth L, Vrachimis A, Wagner S, Breyholz HJ, Faust A, Hermann S, Kopka K, Faber C, Dollé F, Pappata S, Planas AM, Tavitian B, Schäfers M, Sorokin LM, Kuhlmann MT, Jacobs AH (2015) Multimodal imaging reveals temporal and spatial microglia and matrix metalloproteinase activity after experimental stroke. J Cereb Blood Flow Metab 35:1711–1721PubMedPubMedCentralCrossRef

29.

Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R (1994) ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb Vasc Biol 14:133–140CrossRef

30.

Andrés-Manzano MJ, Andrés V, Dorado B (2015) Oil Red O and hematoxylin and eosin staining for quantification of atherosclerosis burden in mouse aorta and aortic root. Methods Mol Biol Clifton 1339:85–99CrossRef

31.

Karunakaran D, Geoffrion M, Wei L, Gan W, Richards L, Shangari P, DeKemp EM, Beanlands RA, Perisic L, Maegdefessel L, Hedin U, Sad S, Guo L, Kolodgie FD, Virmani R, Ruddy T, Rayner KJ (2016) Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci Adv 2:e1600224PubMedPubMedCentralCrossRef

32.

Ohshima S, Petrov A, Fujimoto S, Zhou J, Azure M, Edwards DS, Murohara T, Narula N, Tsimikas S, Narula J (2009) Molecular imaging of matrix metalloproteinase expression in atherosclerotic plaques of mice deficient in apolipoprotein E or low-density-lipoprotein receptor. J Nucl Med 50:612–617PubMedCrossRef

33.

Tavakoli S, Razavian M, Zhang J, Nie L, Marfatia R, Dobrucki LW, Sinusas AJ, Robinson S, Edwards DS, Sadeghi MM (2011) Matrix metalloproteinase activation predicts amelioration of remodeling after dietary modification in injured arteries. Arterioscler Thromb Vasc Biol 31:102–109PubMedCrossRef

34.

Zhang J, Nie L, Razavian M, Ahmed M, Dobrucki LW, Asadi A, Edwards DS, Azure M, Sinusas AJ, Sadeghi MM (2008) Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation 118:1953–1960PubMedPubMedCentralCrossRef

35.

Razavian M, Tavakoli S, Zhang J, Nie L, Dobrucki LW, Sinusas AJ, Azure M, Robinson S, Sadeghi MM (2011) Atherosclerosis plaque heterogeneity and response to therapy detected by in vivo molecular imaging of matrix metalloproteinase activation. J Nucl Med 52:1795–1802PubMedCrossRef

36.

Fujimoto S, Hartung D, Ohshima S, Edwards DS, Zhou J, Yalamanchili P, Azure M, Fujimoto A, Isobe S, Matsumoto Y, Boersma H, Wong N, Yamazaki J, Narula N, Petrov A, Narula J (2008) Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am Coll Cardiol 52:1847–1857PubMedCrossRef

37.

Schäfers M, Riemann B, Kopka K et al (2004) Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 109:2554–2559PubMedCrossRef

38.

Kiugel M, Hellberg S, Käkelä M, Liljenbäck H, Saanijoki T, Li XG, Tuomela J, Knuuti J, Saraste A, Roivainen A (2018) Evaluation of [68Ga]Ga-DOTA-TCTP-1 for the detection of metalloproteinase 2/9 expression in mouse atherosclerotic plaques. Molecules 23:3168PubMedCentralCrossRef

39.

Veseli BE, Perrotta P, De Meyer GRA et al (2017) Animal models of atherosclerosis. Eur J Pharmacol 816:3–13CrossRef

40.

Müller A, Krämer SD, Meletta R, Beck K, Selivanova SV, Rancic Z, Kaufmann PA, Vos B, Meding J, Stellfeld T, Heinrich TK, Bauser M, Hütter J, Dinkelborg LM, Schibli R, Ametamey SM (2014) Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability. Nucl Med Biol 41:562–569PubMedCrossRef

41.

Newby AC (2007) Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 17:253–258PubMedPubMedCentralCrossRef

42.

Schierwagen R, Maybüchen L, Zimmer S et al (2015) Seven weeks of western diet in apoliprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Sci Rep 5:12931PubMedPubMedCentralCrossRef

43.

Duarte S, Baber J, Fujii T, Coito AJ (2015) Matrix metalloproteinases in liver injury, repair and fibrosis. Matrix Biol 44-46:147–156PubMedCrossRef

44.

Dalvie D, Cosker T, Boyden T, Zhou S, Schroeder C, Potchoiba MJ (2008) Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans. Drug Metab Dispos 36:1869–1883PubMedCrossRef

45.

Kuzuya M, Nakamura K, Sasaki T, Wu Cheng X, Itohara S, Iguchi A (2006) Effect of MMP-2 deficiency on atherosclerotic lesion formation in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 26:1120–1125PubMedCrossRef

46.

Johnson JL, George SJ, Newby AC, Jackson CL (2005) Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A 102:15575–15580PubMedPubMedCentralCrossRef

47.

Van Wart HE, Birkedal-Hansen H (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 87:5578–5582PubMedPubMedCentralCrossRef

48.

Jackson CL (2007) Defining and defending murine models of plaque rupture. Arterioscler Thromb Vasc Biol 27:973–977PubMedCrossRef

Titel: Selective Imaging of Matrix Metalloproteinase-13 to Detect Extracellular Matrix Remodeling in Atherosclerotic Lesions
verfasst von: Ariel Buchler
Maxime Munch
Gedaliah Farber
Xiaoling Zhao
Rami Al-Haddad
Eadan Farber
Benjamin H. Rotstein
Publikationsdatum: 06.07.2021
Verlag: Springer International Publishing
Erschienen in: Molecular Imaging and Biology / Ausgabe 1/2022
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-021-01626-9

Anzeige

Neu im Fachgebiet Radiologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen